October 31, 2013 11:35 AM | 1 min read |
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
In a report published Thursday, BMO Capital Markets analyst Jim Birchenough reiterated an Outperform rating on
Receptos (NASDAQ: RCPT), and raised the price target from $40.00 to $41.00.In the report, BMO Capital Markets noted, “Receptos reported 3Q13 operating results late yesterday and provided an update on key pipeline programs. Net loss per share of $0.88 was in line with our expectations, and the company ended 3Q13 with $80.8M in cash. With primary focus on selective S1P1 modulator RPC1063, recent completion of enrollment to the phase 2 portion of the phase 2/3 RADIANCE trial in relapsing MS (RMS) keeps both the 4Q13 interim analysis and mid-14 complete analysis on track. Following a positive interim analysis, RCPT will amend RADIANCE into a head-to-head two-year trial against Avonex. RCPT also noted that the 1063 phase 2 TOUCHSTONE trial in ulcerative colitis (UC) remains on track for data read out also in mid-2014 Broader pipeline progress is expected in 2014 with IND filing and phase 2 initiation expected for RPC4046 in eosinophilic esophagitis (EoE) and with completion of IND-enabling studies in the oral GLP-1 receptor modulator program as well.”Receptos closed on Wednesday at $28.04.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.